Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 106,113

Document Document Title
WO/2015/069593A1
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatmen...  
WO/2015/070034A1
Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving,...  
WO/2015/068832A1
 Provided are a composition, drug, and food for preventing, treating, and improving the symptoms of dementia. A component contained in isomerized hop extract was discovered to activate microglia. Enhancing the activation of the microgl...  
WO/2015/067782A1
The present invention relates to compound of Formula (I) or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as tryptophan 2,3-dioxygenase (TDO2) i...  
WO/2015/064910A1
The present invention relates to a pharmaceutical composition containing, as an active ingredient, a rice extract with high contents of antioxidant polyphenols for preventing and treating degenerative brain diseases. More specifically, e...  
WO/2015/064714A1
The present invention provides a compound that has autotaxin-inhibiting activity and is represented by formula (I) (where R1, R2, R3, R4, and R5 are as defined in the description), a drug comprising the compound as an active ingredient, ...  
WO/2015/063318A1
The present invention relates to the treatment of patients afflicted with Amyotrophic Lateral Sclerosis (ALS), wherein said patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masi...  
WO/2015/065547A1
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a...  
WO/2015/062803A1
The present invention relates to a peptide based compound and its use in a method of prophylactic or therapeutic treatment of at least one amyloidogenic disease or use in a method of non-invasive in vivo and/or in vitro diagnosis of at l...  
WO/2015/065179A1
The present invention relates to compressed tablets for peroral delivery of the cannabinoid cannabidiol (CBD). More particularly, the invention provides a compressed tablet having a tablet weight of 60-1200 mg, said tablet being composed...  
WO/2015/066172A1
Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage f...  
WO/2015/066627A1
The present invention provides compositions and methods for modulation of neuronal networks in the CNS and/or PNS. In certain embodiments, the invention includes modulation of existing networks or restoring one or more damaged or lost ax...  
WO/2015/061856A1
The invention relates to the use of an isolated peptide of 10 to 32 amino acid residues in length for the treatment of neural injury, wherein the isolated peptide comprises at least 10 to 22 arginine residues. The peptide may be a poly-a...  
WO/2015/064764A1
Provided is an aryloyl(oxy or amino)pentafluorosulfanylbenzene compound having pharmacological action. The present invention relates to an aryloyl(oxy or amino)pentafluorosulfanylbenzene compound represented by general formula (A-I), a p...  
WO/2015/065586A1
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a...  
WO/2015/064842A1
The present invention relates to a pharmaceutical composition for preventing and treating blood-brain barrier disorders and central nervous system diseases containing fluoxetine and vitamin C as active ingredients. Particularly, when a l...  
WO/2015/063177A1
The invention relates to (S)-acyl-4'-phosphopantetheine derivatives, methods of their synthesis, and related medical uses of such compounds. Preferred medical uses relate to the treatment of neurodegenerative diseases, such as PKAN.  
WO/2015/064573A1
Provided are a compound represented by formula (I) or (II), a salt thereof, or solvates of the compound and salt, having an analgesic effect and high metabolic stability. Further provided are the following: an analgesic obtained from the...  
WO/2015/062391A1
The present invention provides pyrazolopyrimidone or pyrrolotriazone derivatives, method of preparing same, and pharmaceutical applications thereof. Specifically, the present invention provides pyrazolopyrimidone or pyrrolotriazone deriv...  
WO/2015/064580A1
Provided is a sulfonamide derivative represented by general formula (1) [wherein A, B, D, E, R41 and a to h are each as defined in the description], which has a highly selective α4 integrin inhibitory effect, i.e., being less effective ...  
WO/2015/066344A1
Provided are 5-HT2C receptor agonists. Also provided are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Wil...  
WO/2015/066696A1
The present invention relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegene...  
WO/2015/063775A1
The present invention relates to compositions and methods for modulating autophagic cell death, particularly by regulating alpha-1- antitrypsin activity, thereby useful for treating autophagy-associated diseases. In particular, the prese...  
WO/2015/062555A1
Disclosed are a compound of formula I having higher inhibition of protein kinase G (PKG) activity and pharmaceutically acceptable salts thereof. In formula I, R1 and R2 are the same or different, each being independently chosen from the ...  
WO/2015/064447A1
 [Problem] The purpose of the invention is to provide a drug effective in the treatment and prevention of diseases and the like caused by a decrease in frataxin production. [Solution] The invention provides a frataxin enhancer containi...  
WO/2015/059697A1
The invention provides compositions comprising choline and water soluble derivatives thereof, processes for their preparation from natural sources and uses thereof.  
WO/2015/058536A1
Disclosed in the present invention is the use of a recombinant ganoderma immunomodulatory protein (rLZ-8) in preparing drugs for treating Parkinson's disease. Animal model experiments show that the recombinant ganoderma immunomodulatory ...  
WO/2015/060430A1
The purpose of the present invention is to provide a method for screening substances that participate in metabolic conversion and a kit for screening substances that participate in metabolic conversion. Said problem can be solved with mu...  
WO/2015/060333A1
Provided is a peptide characterized by having a structure, wherein a peptide that comprises an amino acid sequence represented by formula (I) is attached to the C-terminal side of a peptide that forms an α-helix, or a salt thereof: (I) ...  
WO/2015/061779A1
Methods for treating a subject in need thereof are provided which include administering a pharmaceutical composition comprising a protein transduction reagent-modified reprogramming protein to the subject, wherein the protein transductio...  
WO/2015/061328A3
The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyal...  
WO/2015/060368A1
The present invention addresses the problem of providing a compound which has a PDE2A inhibitory action and is useful as an agent for preventing or treating schizophrenia, Alzheimer's disease, etc. The present invention relates to a comp...  
WO/2015/061792A1
Compounds having the following formula (E): Formula E or a pharmaceutically acceptable salt thereof, wherein R, R', R'', X and n are as defined herein are provided. Methods comprising use of such compounds for the treatment of neurologic...  
WO/2015/059632A1
Provided herein are methods for treating a neurodegenerative disease or disor- der, or stroke using a combination of one or more RXR agonist and/or one or more Nurr1 agonist and one or more trophic factor, or pharmaceutically acceptable ...  
WO/2015/060365A1
Provided is a compound represented by formula (1), with which it is possible to perform tau imaging with a high specificity to tau, and with excellent sensitivity, while having high brain uptake, low or non-existent bone-seeking properti...  
WO/2015/060348A1
The present invention relates to a cyclic aminomethyl pyrimidine derivative and a pharmacologically acceptable salt thereof which have a highly selective action on a dopamine D4 receptor and are useful as a therapeutic agent for attentio...  
WO/2015/059432A1
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain di-isopropyl-phosphinoyl- alkanes as described herein (DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9...  
WO/2015/061317A1
The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subjec...  
WO/2015/061421A1
This disclosure relates to deuterated bile acid compositions. A deuterated compound is selected from the disclosed groups of bile acids and their derivatives, analogs and salts. At least one of the hydrogen atoms in the compound is repla...  
WO/2015/060313A1
 The invention provides a preparation having controlled release ability with excellent production uniformity, handling properties, and productivity; and a method for producing the same. The invention pertains to a preparation having co...  
WO/2015/060746A1
The invention relates to the field of pharmacology and applied medicine, and specifically to the combined application of medicinal preparations which have a neurotrophic effect and which reduce manifestations of psychiatric, behaviora...  
WO/2015/058258A1
48 Abstract The present invention relates to an Aβ modulating peptide comprising a peptide selected from the list of peptides comprising: (i) Arg-Lys-Leu-Met-Gln-Pro-Thr-Arg-Asn (SEQ ID NO:1); (ii) Arg-Lys-Leu-Met-Gln-Pro-Thr-Arg-Asn-Ar...  
WO/2015/058868A1
The invention relates to anti-tumor compounds which have been designed to functionally disrupt the cross-talk between AEG-1 and the p65 subunit of NF-κB. Therefore, the invention relates to methods and compositions for the treatment of ...  
WO/2015/056675A1
 Exceptional antidepressant action, improving action on cognitive function associated with depression, improving action on suppression of stress-induced Akt activation, and suppressive action on stress-induced GSK-3β activation are ob...  
WO/2015/056094A3
The present patent application relates to a pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent. Particularly, the present patent application provides a pharmaceutical composition comprising a thienopyrimidine...  
WO/2015/055770A1
The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4- tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions com...  
WO/2015/054730A1
A composition comprising two or more active agents in a micro-dose amount, such as a micro- dose of naltrexone in combination with a micro-dose of flumazenil, in the treatment of craving or anxiety resulting in rapid settling of the crav...  
WO/2015/057939A1
Antibodies and antibody fragments thereof that specifically bind to sphingosine-1-phosphate receptor 4 (S1P4) are disclosed. Also disclosed are methods of using these anti-S1P4 antibodies and antibody fragments to treat or prevent neurol...  
WO/2015/056922A1
The present invention relates to a composition for improving, preventing or treating cranial nerve diseases, including an extract of brassica oleracea as an effective component. According to the present invention, the composition has a s...  
WO/2015/057662A1
Compositions including a combination of a source of choline, a source of magnesium, and a source of L-tryptophan are provided for improving cognitive performance in a subject. The compositions may improve a cognitive impairment and/or br...  

Matches 301 - 350 out of 106,113